Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase NA 3Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7Genitourinary 5Thoracic 4CNS 4Gynecologic 3Gastrointestinal 3Plasma cell 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 21fludarabine 12Rituximab 10Vincristine 6Etoposide 6Prednisone 5Doxorubicin 5pembrolizumab 4Radiotherapy 4Methotrexate 4Magnetic Resonance Spectroscopy 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Dexamethasone 4venetoclax 3ibrutinib 3Nivolumab 3Imiquimod 3Ifosfamide 3Exercise 3Biopsy 368Ga-pentixafor 3fludarabine phosphate 2daratumumab 2Transplantation 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Roflumilast 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Fluorodeoxyglucose F18 × Lymphoid × Clear all
NCT02405078 2022-10-28

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
35 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡